Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report) was upgraded by stock analysts at Zacks Research to a “hold” rating in a report released on Wednesday,Zacks.com reports.
Oxford BioMedica Stock Down 7.5%
OXBDF opened at $8.00 on Wednesday. The company has a fifty day moving average price of $8.07 and a two-hundred day moving average price of $8.94. Oxford BioMedica has a 52 week low of $5.17 and a 52 week high of $12.61.
About Oxford BioMedica
Oxford BioMedica is a clinical-stage gene and cell therapy company headquartered in Oxford, United Kingdom. The company specializes in the development, manufacturing and commercialization of lentiviral vector delivery systems for use in treating serious diseases. Its proprietary LentiVector® platform underpins both in-house development programs and third-party collaborations, enabling the stable integration of therapeutic genes into target cells.
In its research pipeline, Oxford BioMedica is advancing candidates across ophthalmology, neuroscience and oncology indications.
See Also
- Five stocks we like better than Oxford BioMedica
- Microsoft Earnings Are Coming—But Azure and CapEx Will Decide the Reaction
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
